Clinical Researchers Can Now Easily Transform Raw NGS Data into
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE:A) today introduced SureCall
version 2.0 software, expanding the capabilities of the company's
current market-leading, next-generation sequencing target-enrichment
solutions. The newly upgraded software features compatibility with
SureSelect custom target-enrichment and Human All Exon panels.
One of the biggest challenges faced by clinical research labs when
adopting next-generation sequencing methods is ensuring highly accurate
analysis of complex data samples and identifying biologically
significant variants. SureCall software enables clinical researchers to
transform raw NGS data into insightful analyses without requiring
advanced bioinformatics training or laboratory infrastructure.
"In NGS clinical cancer research, analysis is the key," said Dr. Robert
Ohgami, of Stanford University School of Medicine's Department of
Pathology. "We rely heavily on SureCall to analyze sequencing data in
our hematologic myeloid neoplasms studies. It enables rapid alignment
and base calling for reporting significant mutations, and data output is
in a simple tabular format."
"Demand for clinical research labs to adopt next-generation sequencing
technologies is at an all-time high," said Victor Fung, senior director
of marketing for Agilent's Genomics Solutions Division. "But fast,
efficient data analysis is a potential roadblock for both in-house
bioinformatics teams and for those outsourcing data analysis. SureCall
can help by reducing both set-up time and external bioinformatics spend."
SureCall software is ideally suited for clinical research labs that are
not accustomed to performing complex, in-house bioinformatics analyses.
The platform enables users to easily analyze data with their own desktop
computers and also accommodates various security access levels.
SureCall 2.0 features enhanced exome analysis for both SureSelect and
HaloPlex. With customizable algorithms in the software, users can easily
identify copy number changes and somatic mutations in tumors when
comparing them to normal sample analyses and de-novo mutations with trio
SureCall v2.0 is available online and free-of-charge to HaloPlex and
SureSelect users. The application can be downloaded by visiting
version 2.0 software.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world's premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company's 20,600
employees serve customers in more than 100 countries. Agilent had
revenues of $6.8 billion in fiscal 2013. Information about Agilent is
available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic
measurement business. The new company is named Keysight Technologies,
Inc. The separation is expected to be completed in early November 2014.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
Source: Agilent Technologies Inc.